Evaluation of the effectiveness of the appointment of acetylsalicylic acid for the prevention of obstetric complications by the method of logistic regression
- 1. Kyiv Perinatal Center, Kyiv, Ukraine
- 2. National medical university named by O.О. Bogomolets, Kyiv, Ukraine
- 3. National Bank of Ukraine, Kyiv, Ukraine
Description
Preeclampsia remains to be an urgent problem in the modern medicine, the main reason for which is the lack of high efficiency of treatment. One of the few methods with proven effectiveness is the prophylactic administration of aspirin at the beginning of the second trimester of pregnancy. At the same time, microcirculation disorders that underlie the development of preeclampsia are pathogenetically significant for other gestational complications.
The objective: a study of the effectiveness of aspirin prescription for the prevention of preeclampsia and other complications during pregnancy using the logistic regression method.
Materials and methods. The control group included 43 pregnant women with clinical criteria for preeclampsia. Forty six pregnant women with risk factors for preeclampsia who took acetylsalicylic acid from the 16-18 weeks of gestation formed the I group, and 46 pregnant women with risk factors for preeclampsia who did not take acetylsalicylic acid were included in the the II group. In all patients, on the basis of anamnesis data, risk factors and the course of the second trimester of pregnancy were analyzed, their correlation analysis and the use of acetylsalicylic acid were carried out, logistic regressions and simple decision trees were constructed.
Results. The proposed logistic regression models have demonstrated their veracity by confirming the influence of traditional risk factors for the development of preeclampsia. At the same time, the use of these models allowed not only to prove the preventive effect of aspirin on the development of preeclampsia (the coefficient is statistically significant, with a negative sign), but also the ability to reduce the severity of preeclampsia. In addition, the negative sign of the coefficient was obtained when studying the effect of taking aspirin on such complications of pregnancy as premature birth and fetal growth retardation.
Conclusions. 1. The use of a database of patients, statistical and model analysis of this dataset, allows you to establish and evaluate the relationship, their statistical significance between different factors. Based on the results of the research we can say with great confidence about the significant effect of prophylactic aspirin intake on reducing the risk of preeclampsia. 2. Taking aspirin reduces the likelihood of fetal growth retardation and premature birth. 3. The use of assisted reproductive technologies is positively correlated with the risk of developing preeclampsia.
The influence of other traditional factors on the development of preeclampsia was proved by the method of logistic regression, which confirms the veracity of the proposed statistical model.
Files
Evaluation of the effectiveness of the appointment of acetylsalicylic acid for the prevention of obstetric complications by the method of logistic regression.pdf
Files
(538.6 kB)
Name | Size | Download all |
---|---|---|
md5:3f3c0de61a7a436cae225e179b13a9ce
|
538.6 kB | Preview Download |
Additional details
References
- ACOG "Low-Dose Aspirin Use During Pregnancy", Committee Opinion CO Number 743. July 2018.
- American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013. Available from: http://www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Hypertension-in-Pregnancy
- Bakhti, A., Vaiman, D. Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertens Res. 2011;34:1116–20. Available from: https://doi.org/10.1038/hr.2011.111
- Benigni A, Gregorini G, Frusca T, Chiabrando C, Ballerini S, Valcamonico A, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med. 1989;321:357–62.
- Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. ObstetGynecol. 2010;116:402–14.
- Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137–41.
- National Institute for Health and Care Excellence. Hypertension in pregnancy: quality standard . Manchester (United Kingdom): NICE; 2013. Available from: https://www.nice.org.uk/guidance/qs35/resources/hypertension-in-pregnancy-2098607923141
- Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287–94.
- Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J ObstetGynecol. 2017;218:287–93.e1
- Roberge S, Nicolaides KH, Demers S, Villa P, Bujold E. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound ObstetGynecol. 2013;41:491–9.
- Rolnik, D. et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. 2017. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1704559
- Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med. 1989; 321:351–6.
- Talari, H., Mesdaghinia, E., Kalahroudi, M. Aspirin and Preeclampsia Prevention in Patients With Abnormal Uterine Artery Blood Flow. 2014. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222009/
- World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia . Geneva (Switzerland): WHO; 2011. Available from: http://apps.who.int/iris/bitstream/10665/44703/1/9789241548335_eng.pdf